A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Liebowitz, Michael R ^a   Tourian, Karen A ^b   Hwang, Eunhee ^b   Mele, Linda ^b  

^a Howard Hughes Medical Institute   (United States)

^b PFIZER INC   (United States)

Author keywords

Adult; Antidepressive agents; Depression; Drug safety; Efficacy; Treatment

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ABSCESS; ADULT; ANKLE EDEMA; APPENDICITIS; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; NONCARDIAC CHEST PAIN; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SCROTUM ABSC; SCROTUM ABSCESS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84875199737     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-94     Document Type: Article

References (21)

1. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatr 2010, 71:e06.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV 1994, Washington, DC: American Psychiatric Association, American Psychiatric Association.
4. Pristiq [package insert] 2011, Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc.
5. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatr 2007, 68:1663-1672.
6. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatr 2007, 68:677-688.
7. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007, 22:338-347.
8. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008, 23:243-253.
9. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008, 24:1877-1890.
10. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009, 31(Pt 1):1405-1423.
11. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009, 14:41-50.
12. Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010, 30:18-24.
13. Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, . for the Study 3359 Investigators Efficacy and safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013, 19:5-14. for the Study 3359 Investigators.
14. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology 1976, 217-222. Rockville, MD: US Department of Health, Education, and Welfare.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
16. Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003, 191:211-218.
17. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
18. Moller HJ. Rating depressed patients: observer- vs self-assessment. Eur Psychiatr 2000, 15:160-172.
19. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006, 8:207-215.
20. Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol 2011, 26:75-83.
21. Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatr 2009, 11:8-15.